Skip to main content

Volume 3 Supplement 1


Effects of levosimendan on cellular metabolic alterations in patients with septic shock: a randomised controlled study


Mitochondrial dysfunction and consequent cellular energetic failure play a key role in the development of sepsis-related organs failure. Levosimendan, by a calcium-sensitizing mechanism increases myocardial contractility while simultaneously exerting vasodilatory properties via activation of ATP-dependent potassium channels (KATP) [1].


The aim of the present study was to evaluate the effects of levosimendan on muscle metabolism compared with placebo and dobutamine in patients with spetic shock.


The study was designed as a prospective, double-blind, placebo-controlled, clinical trial and performed in a Tunisian medical surgical intensive care unit. After achieving normovolemia and a mean arterial pressure of at least 65 mmHg, 30 septic shock patients were randomized to one of three intravenous treatment groups: levosimendan 0.2 µg/kg/min (n = 10), dobutamine 5 µg/kg/min (n = 10) or placebo (n = 10). Systemic hemodynamic monitoring of the patients included a central venous catheter, a radial artery catheter and a pulmonary artery catheter. A microdialysis probe was placed into the femoral quadriceps and samples were collected at baseline (before drugs adminstration) and every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.


Baseline characteristics, including age, gender, body weight, and Cause of septic shock, as well as onset time of septic shock, IGSII, and mortality were not different among groups. In addition, there was no significant difference between groups at baseline (H0) in any of the investigated hemodynamic or MD metabolites variables. Levosimendan group had a greater decrease in L/P ratio and a greater increase in MD pyruvate at the 72 th 72th hour compared with the placebo group (p = 0.043). Tissue lactate clearance was significantly increased in the levosimendan arm compared with the placebo arm at 54th, 60th and 72th hours of the study ( H54 p = 0.036 ; H60 p = 0.043 ; H72 p = 0.041). From 48th to 72th hours, Tissue L/P clearance was significantly higher in levosimendan-treated patients compared with placebo (H48 (p = 0.015), H54 (p = 0.032), H60 (p = 0.016) et à H72 (p = 0.007)). Tissue L/P clearance Tissue L/P clearance was higher in Levosimendan group than in dobutamine group at 72th hour (p = 0.006).


Our results demonstrate that levosimendan improves Cellular metabolic alterations.

Our data suggest that levosimendan may protect mitochondria from oxidative stress and maintain cellular energy homeostasis during septic shock by opening mitochondrial KATP channels.


  1. Kivikko , et al: Circulation. 2003, 107: 81-6. 10.1161/01.CIR.0000043245.00859.11.

    PubMed  CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Meddeb, B., Hajjej, Z., Romdhani, C. et al. Effects of levosimendan on cellular metabolic alterations in patients with septic shock: a randomised controlled study. ICMx 3 (Suppl 1), A811 (2015).

Download citation

  • Published:

  • DOI:


  • Septic Shock
  • Dobutamine
  • KATP Channel
  • Levosimendan
  • Septic Shock Patient